Capricor Therapeutics, Inc. (CAPR) Financial Analysis & Valuation | Quarter Chart
Capricor Therapeutics, Inc. (CAPR)
CAPRPrice: $29.07
Fair Value: 🔒
🔒score
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, whic... more
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of t... more
Description
Shares
| Market Cap | $1.33B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Linda Marbán |
| IPO Date | 2007-02-13 | CAGR | — |
| Employees | 160 | Website | www.capricor.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CAPR chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.66B | P/E Ratio | — |
| Forward P/E | -38.42 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 5.99 |
| P/CF Ratio | -18.02 | P/FCF Ratio | -11.66 |
| EPS | $-2.32 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.59% | ROA | -0.35% |
| ROCE | -0.41% | Current Ratio | 8.42 |
| Quick Ratio | 8.42 | Cash Ratio | 3.13 |
| Debt/Equity | 0.08 | Interest Coverage | -39.38 |
| Altman Z Score | 14.91 | Piotroski Score | 2 |